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Successful differential diagnosis of primary versus metastatic 
pulmonary adenocarcinomas by using gene mutation analyses: 
report of a case
Nakazato, Yoshimasa1 Tanaka, Ryota1 Minato, Koichi2 Kato, Masahiko3 
Yoshizumi, Masakazu3 Goya, Tomoyuki4 
1 Department of Thoracic Surgery, Gunma Prefectural Cancer Center, 
Ohta, Japan 2 Department of Chemotherapy, Gunma Prefectural Can-
cer Center, Ohta, Japan 3 Gunma Prefectural Institute of Public Health 
and Environmental Sciences, Maebashi, Japan 4 Department of Surgery, 
Kyorin University School of Medicine, Mitaka, Japan 
The differential diagnoses for primary or metastatic pulmonary 
malignant lesions are often difﬁcult. We used the patterns of some 
genetic alterations as a discrimination marker of multiple lung lesions. 
A 61-year-old Japanese woman underwent total thyroidectomy for 
the left thyroid cancer in 2004. The next year, she underwent a partial 
mastectomy for the right breast cancer without pathological nodal inva-
sions. As postoperative treatment, she had radiotherapy with 50Gy for 
local controls, and was treated with sequential chemotherapy by orally 
uracil and tegaful. After eight months, chest computed tomography 
(CT) by follow-up revealed two small nodules in the left lower lobe 
(the segments of S9 and S10, 10mm and 8mm, respectively). We clini-
cally diagnosed those lesions as metastatic lung cancer from treated the 
malignant lesions. She underwent partial pulmonary resections by us-
ing video assisted thoracoscopic approach for the malignant lesions on 
December 4, 2006. A nodule in the segment of S10 was pathologically 
diagnosed as primary lung cancer, but another nodule in the segment 
of S9 was pathologically diagnosed as poorly differentiated adeno-
carcinoma. Especially the S9 nodule morphologically was not able to 
judge by microscopic examination, whether primary lung cancer or 
metastatic lesions from the treated breast cancer. DNAs were extracted 
from parafﬁn-embedded tissue from each of the tumor. Direct sequenc-
ing analysis of p53 gene from exons 5-8 using genomic DNA and K-ras 
from codon 12 were performed for the differential diagnoses. A differ-
ent pattern of the distribution of p53 mutation in the two nodules was 
observed, and a same pattern of the distribution of p53 mutation was 
observed in the DNA samples of the S9 nodule and the treated breast 
cancer. The mutation was C to T pointmutation in codon 213 on the 
two lesions. However, K-ras mutation was not detected in each of the 
tumor sample. So, we diagnosed the S9 nodule as metastatic pulmonary 
carcinoma from the treated breast cancer on the result of p53 mutation 
analyses. When we especially need to differentiate between primary 
and metastasis for the diagnoses of multiple lung lesions, it is useful 
that the patterns of some genetic alterations are analyzed.
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Immunohistochemical expression of Cap43 protein in pathological 
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Purpose: Cap43 is a 43Kda molecular weight protein induced in calci-
um, whose expression is induced in hypoxia, metallic ion, retinoid, p53 
and phorbol ester. Cap43 protein is expressed in a variety of organs, 
and in particular expression of Cap43 protein is high in prostate, ovary, 
colon and kidney. It is also reported that overexpression of Cap43 sup-
presses of metastasis and tumor growth of some malignancies, but its 
precise role remains unclear and there is not the report that elucidate 
the expression of Cap43 protein in lung cancer. In this study, expres-
sion of Cap43 protein in pathological stageIA non-small cell lung 
cancer (NSCLC) was evaluated using immunohistochemical staining 
and the relationship between Cap43 expression and clinicopathologic 
ﬁndings was examined.
Materials and Methods: Surgical resected specimens from 74 patients 
with pathological stageIA NSCLC were studied. All patients underwent 
surgical resection between January 1 1995 and December 312001in 
Department of Surgery at the Kurume University Hospital, Japan. 
Among these patients, 64 underwent lobectomy and 9 underwent wedge 
resection. NSCLC tissues (adenocarcinoma, 57; squamaous cell carci-
noma, 16; Unknown, 1) were obtained from 39 men and 35 women with 
a mean age of 66years (age range 45-84 years). Each tissue underwent 
immunohistochemical analysis using antibodies to Cap43. Expression of 
Cap43 protein was evaluated with cytoplasm and nucleus. Differences in 
survival rates and relapse-free survival were evaluated by log rank test. 
Results: Expression of Cap43 protein was not found in pulmonary nor-
mal tissue and found in only carcinoma tissue. Incidence rate in nucleus 
was 59.5% (44/74). Overexpression rate with cytoplasm was 71.6% 
(53/74). In recurrence cases, incidence rate in nucleus was 80% (16/20) 
and the overexpression rate with cytoplasm was 81% (17/20). On the 
other hand, in non-recurrence cases, incidence rate in nucleus was 52% 
(28/54) and the overexpression rate with cytoplasm was 68% (36/54). As 
for the ﬁve-year survival rate, the group of the expression of Cap43 pro-
tein in nucleus was 77.3% and the group of the no-expression of Cap43 
protein in nucleus was 85.7%. There was no statistical signiﬁcance dif-
ference (p=0.59). The group of the over expression of Cap43 protein with 
cytoplasm was 77.4% and the group of the non-overexpression of Cap43 
protein with cytoplasm was 85.7%. There was no statistical signiﬁcance 
difference (p=0.47). As for the relapse free survival, the group of the 
expression of Cap43 protein in nucleus was 68.2% and the group of the 
no-expression of Cap43 protein in nucleus was 80.0%. There was no 
statistical signiﬁcance difference (p=0.32). The group of the over expres-
sion of Cap43 protein with cytoplasm was 69.8% and the group of the 
non-overexpression of Cap43 protein with cytoplasm was 81.0%. There 
was no statistical signiﬁcance difference (p=0.37).
Summary: Our results suggest that Cap43 protein to be a likely tumor 
marker for NSCLC. 
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P53 codon 72 polymorphism and human papillomavirus infection 
in non-small cell lung cancer: associated with viral oncogene e6 
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A polymorphism at codon 72 of the p53 tumor suppressor gene is as 
a possible determinant for cancer risk and particularly carcinomas 
